Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
Hélène Marijon(Cedars-Sinai Medical Center), Harold Phillip Koeffler(Cedars-Sinai Medical Center)
Cited by 19